Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around
Principal Investigator
by Zev A. Wainberg, MD (ucla)
Headshot of Zev A. Wainberg
Zev A. Wainberg

Description

Summary

The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are:

  • to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part)
  • to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part)

Participants will receive:

i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.

Official Title

A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients With KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma (KISIMA-02)

Details

This is an open-label, phase 1b study to evaluate the safety, tolerability, immunogenicity and preliminary efficacy of a heterologous prime-boost vaccine (protein and viral vector) regimen without/with the PD-1 inhibitor Ezabenlimab.

COMPLETED - Part A (metastatic and locally advanced PDAC patients) Cohort A: ATP150/ATP152 and VSV-GP154 treatment

ONGOING - Part B (locally advanced and resected PDAC patients) Cohort B: ATP150/ATP152, Ezabenlimab and VSV-GP154 treatment Cohort B1, B2, B3: dose escalation

NOT STARTED YET - Part C (resected PDAC patients) Cohort C: ATP150/ATP152, Ezabenlimab and VSV-GP154 treatment (treatment versus observational arm)

Keywords

Pancreatic Ductal Adenocarcinoma, KISIMA-02, PDAC, ATP150, ATP152, Ezabenlimab, VSV-GP154, Adjuvant setting, Resected pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Locally advanced pancreatic ductal adenocarcinoma, Resected PDAC, Metastatic PDAC, LAPC, Adenocarcinoma

Eligibility

Locations

  • University of California Los Angeles (UCLA) accepting new patients
    Los Angeles California 90095 United States
  • USC/Norris Comprehensive Center accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at University of California Health

  • Zev A. Wainberg, MD (ucla)
    Zev Wainberg, M.D., holds the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amal Therapeutics
ID
NCT05846516
Phase
Phase 1 Pancreatic Ductal Adenocarcinoma Research Study
Study Type
Interventional
Participants
Expecting 85 study participants
Last Updated